CYTEA

CYTEA BIO is a preclinical-stage biotechnology company specializing in innovative ligand-driven immunotherapies that leverage unmodified allogeneic cells as effector entities. The company has developed and patented a versatile and modular therapeutic platform known as the Pin™ Platform... Our approach stands out with its unique advantages, including enhanced potency, achieved through pre-arming cells for precise target-specific action, ensuring efficacy independent of patients' immune system variability... Our innovative approach combines Fc-engineered targeting ligands with genetically unmodified effector cells, enabling precise targeting, potentially enhancing treatment efficacy while reducing toxicity.

Primary location: Grabels France